RAPP Form 144: Insider Sale of 52,501 Shares ($1.38M)

Rapport Therapeutics, Inc. (RAPP) filed a Form 144 reporting a proposed sale of 52,501 common shares, representing part of its outstanding stock, with an aggregate market value of $1,375,001.19.

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. (RAPP) filed a Form 144 reporting a proposed sale of 52,501 common shares, representing part of its outstanding stock, with an aggregate market value of $1,375,001.19. The sale is to be handled through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 09/17/2025. The shares were acquired on 12/02/2022 under an RSA from the issuer. The filer reports no securities sold in the past three months and provides the standard attestation about material nonpublic information.

Positive

• Clear disclosure of number of shares (52,501) and aggregate market value ($1,375,001.19)
• Broker and venue identified (Morgan Stanley Smith Barney LLC; NASDAQ) providing execution clarity
• Acquisition provenance stated (RSA on 12/02/2022) which helps traceability
• No sales in past three months reported, reducing ambiguity about recent insider trading

Negative

• No information on the identity or role of the selling person beyond acquisition details
• No trading-plan date provided; if relying on Rule 10b5-1 this is not specified
• No context on percentage ownership or impact on outstanding shares beyond raw counts

Insights

Securities Analyst

TL;DR: Routine Form 144 reporting an insider sale of 52,501 shares valued at $1.375M; appears administrative rather than market-moving.

This filing documents a proposed sale under Rule 144 by a person who acquired shares via a restricted stock award on 12/02/2022. The broker is identified as Morgan Stanley Smith Barney and the execution venue is NASDAQ with an approximate sale date of 09/17/2025. No sales in the prior three months were reported. From an analyst perspective, the filing provides clear transfer provenance and timing but contains no financial performance metrics or changes in control.

Corporate Governance Expert

TL;DR: Disclosure meets Rule 144 form requirements; provides acquisition details and broker information but no governance red flags.

The filer states the shares were acquired through an RSA from the issuer and certifies lack of material nonpublic information. The form lists broker and planned execution date, and indicates zero related sales in the past three months. For governance review, the document is procedural and compliant in content; it does not disclose additional contextual information about insider role or any trading plan adoption date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Rapport Therapeutics Form 144 report for RAPP?

The form reports a proposed sale of 52,501 common shares valued at $1,375,001.19 to be executed via Morgan Stanley Smith Barney LLC on NASDAQ around 09/17/2025.

When and how were the shares being sold acquired?

The shares were acquired on 12/02/2022 as a restricted stock award (RSA) from the issuer, and the filing lists the amount as 52,501 shares.

Did the filer report any securities sold in the past three months?

No. The Form 144 states "Nothing to Report" for securities sold during the past three months.

Which broker and exchange are named in the filing?

The broker is Morgan Stanley Smith Barney LLC, Executive Financial Services and the exchange is listed as NASDAQ.

Does the filing state whether the seller knows material nonpublic information?

Yes. The signer represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/17/2025 - 04:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001722140
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	RAPPORT THERAPEUTICS INC
SEC File Number	001-42121
Address of Issuer	99 High Street, Suite 2100 Boston MASSACHUSETTS 02110
Phone	8573218020
Name of Person for Whose Account the Securities are To Be Sold	ABRAHAM CEESAY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	52501	1375001.19	36497920	09/17/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/02/2022	RSA	Issuer			52501	12/02/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/17/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/12/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Abraham Ceesay
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)